Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Avidity Biosciences Inc (NASDAQ: RNA) closed at $42.34 up 3.12% from its previous closing price of $41.06. In other words, the price has increased by $3.12 from its previous closing price. On the day, 2.2 million shares were traded. RNA stock price reached its highest trading level at $42.795 during the session, while it also had its lowest trading level at $40.11.
Ratios:
For a deeper understanding of Avidity Biosciences Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.26 and its Current Ratio is at 9.26. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Roth Capital on September 17, 2025, initiated with a Buy rating and assigned the stock a target price of $62.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 15 ’25 when McCarthy Teresa sold 15,000 shares for $41.41 per share. The transaction valued at 621,142 led to the insider holds 97,130 shares of the business.
Hughes Steven George sold 1,542 shares of RNA for $70,022 on Sep 15 ’25. The Chief Medical Officer now owns 38,867 shares after completing the transaction at $45.41 per share. On Sep 11 ’25, another insider, Flanagan W. Michael, who serves as the Chief Scientific Officer of the company, sold 20,000 shares for $38.94 each. As a result, the insider received 778,702 and left with 80,195 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 6177547776 and an Enterprise Value of 4269173248. For the stock, the TTM Price-to-Sale (P/S) ratio is 575.73 while its Price-to-Book (P/B) ratio in mrq is 4.29. Its current Enterprise Value per Revenue stands at 397.91 whereas that against EBITDA is -8.23.
Stock Price History:
The Beta on a monthly basis for RNA is 0.96, which has changed by -0.037727296 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, RNA has reached a high of $56.00, while it has fallen to a 52-week low of $21.51. The 50-Day Moving Average of the stock is 1.17%, while the 200-Day Moving Average is calculated to be 26.07%.
Shares Statistics:
For the past three months, RNA has traded an average of 3.21M shares per day and 5400930 over the past ten days. A total of 145.90M shares are outstanding, with a floating share count of 131.53M. Insiders hold about 9.85% of the company’s shares, while institutions hold 90.99% stake in the company. Shares short for RNA as of 1756425600 were 17571891 with a Short Ratio of 5.48, compared to 1753920000 on 16212032. Therefore, it implies a Short% of Shares Outstanding of 17571891 and a Short% of Float of 13.780000000000001.
Earnings Estimates
Investors are keenly observing as 16.0 analysts analyze and rate the current performance of Avidity Biosciences Inc (RNA) in the stock market.The consensus estimate for the next quarter is -$1.25, with high estimates of -$0.61 and low estimates of -$2.36.
Analysts are recommending an EPS of between -$3.33 and -$6.26 for the fiscal current year, implying an average EPS of -$4.43. EPS for the following year is -$4.85, with 17.0 analysts recommending between -$2.98 and -$7.31.
